Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Compass

Will Andy Burnham ‘go big’ in expanding the role of the state?

In the first of a series on nationalisation, we look at the critical tests ahead for the PM-in-waiting, from choosing a chancellor to the future of Thames Water

The Guardian - UK

The 30-year fixed mortgage was supposed to be predictable. Two costs quietly broke that promise

A new survey shows 40% of homeowners said they’ve considered moving because their property taxes have gotten so high.

Fortune

Andy Burnham’s long coup: the chaotic year-long project to return him to Westminster

Story of the key figures, decisions, planning and missteps in push to line up Greater Manchester mayor for PM

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

AI is driving an already expensive housing market nuts in San Francisco

IN FOCUS: The AI boom has helped San Francisco turn around its Covid-era woes — but rent hikes and people buying for a million over the listing price is setting nerves on edge, Josh Marcus reports

The Independent UK

This major Makerfield victory has made it inevitable: it’s now time for Keir Starmer to step aside

Andy Burnham’s positive vision has struck a powerful blow to Reform – but the PM risks diminishing the impact by clinging on in No 10, says Neal Lawson of the cross-party campaign organisation Compass

The Guardian - UK

The FDA Just Put Psilocybin and an MDMA-Like Drug on a 1-to-2 Month Approval Track. A Historic Mental Health Decision Is Coming.

FDA issued National Priority Vouchers to Compass Pathways, Usona, and Transcend for psilocybin and methylone in April 2026. A decision could come by late 2026.

Medical Daily

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secon

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances

Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen’s se

MarketBeat

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timel

MarketBeat

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladde

MarketBeat

Can Burnham turn ‘Manchesterism’ into a practical offer for government?

Roots of idea for ‘ending neoliberalism’ have been growing over many months – with many different influences

The Guardian - UK

Thames Water rescue deal threatened by uncertainty over next prime minister

Exclusive: Potential investors fear Andy Burnham could push to bring utility companies into public ownership

The Guardian - UK

Cosan Q1 Earnings Call Highlights

Cosan (NYSE:CSAN) reported a narrower first-quarter net loss and highlighted a series of debt-reduction measures, while management said the holding company remains focused on deleveraging and simplifying its portfolio. Fernando Tinel, Cosan’s Head of Investor Relations and ESG, said the company end

MarketBeat

What could happen next in Labour leadership challenge?

How a contest to become PM is triggered, and Andy Burnham’s chances in the Makerfield byelection

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Compass Pathways Q1 Earnings Call Highlights

Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for a potential launch by the end of the year if the therapy is approved. On the company’s first-quar

The Guardian - UK

Andy Burnham can save Labour and defeat Reform. He should be the next prime minister

Put plainly, the Greater Manchester mayor is electoral gold dust. The Labour party machine must not stand in his way to becoming an MP, says Neal Lawson of the cross-party campaign organisation Compass

Evening Standard

Mixed day for stocks as oil prices climb amid ongoing Iran-US deadlock

The continued stalemate between the US and Iran dashed investors’ hopes of an imminent peace deal and heightened concerns over oil supply disruption.

The Guardian - UK

Most Labour members think Starmer cannot revive party fortunes, poll finds

Exclusive: Mayor of Greater Manchester Andy Burnham is preferred choice of new leader for 42% of those surveyed

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Burnham sparks Labour anger with plan to appear at event alongside Greens

Some MPs accuse Burnham of undermining local election messaging by agreeing to speak at event later this month

MarketBeat

These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

MarketBeat

This 4/20, Wall Street Is Betting on More Than Marijuana

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.

Barchart

Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?

Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic medicines. But is it too late to invest in CMPS shares already?

Homes & Gardens

Orlando Bloom Reworked His Colorful Beach House With Artist Roy McMakin – Now, He's Listed the Vibrant Bolthole for $12 Million

Indoor-outdoor living areas, bold hues, and contemporary art await at the latest celeb home to hit the real estate market

GOBankingRates

America’s 10 Hottest Markets for $10M-Plus Homes, Ranked

The market for $10 million-plus homes is growing. Take a deeper look at the 10 housing markets where the most $10 million-plus homes were sold in 2025.

Barchart

Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks

Cathie Woods’s ARK Invest deploys $19 million across five growth stocks in this uncertain market.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.